EnteroMedics (ETRM) versus BIOLASE (BLTI) Head-To-Head Comparison

EnteroMedics (NASDAQ: ETRM) and BIOLASE (NASDAQ:BLTI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Insider and Institutional Ownership

1.3% of EnteroMedics shares are owned by institutional investors. 5.5% of EnteroMedics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for EnteroMedics and BIOLASE, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EnteroMedics 0 0 1 0 3.00
BIOLASE 0 0 0 0 N/A

EnteroMedics presently has a consensus price target of $11.03, indicating a potential upside of 474.48%. Given EnteroMedics’ higher probable upside, research analysts plainly believe EnteroMedics is more favorable than BIOLASE.

Profitability

This table compares EnteroMedics and BIOLASE’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
EnteroMedics -4,399.48% -167.73% -123.00%
BIOLASE -34.01% -151.86% -43.37%

Valuation & Earnings

This table compares EnteroMedics and BIOLASE’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
EnteroMedics $571,759.00 27.85 -$22.15 million ($16.72) -0.11
BIOLASE N/A N/A N/A N/A N/A

BIOLASE has higher revenue, but lower earnings than EnteroMedics.

Summary

EnteroMedics beats BIOLASE on 5 of the 8 factors compared between the two stocks.

EnteroMedics Company Profile

EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

BIOLASE Company Profile

BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.

Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply